Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; Maintains Operational Guidance at Midpoint, Cuts on Reported Basis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; Maintains Operational Guidance at Midpoint, Cuts on Reported Basis

J&J's cancer drug sales help weather hit from stronger dollar

July 19, 2022 6:27 AM EDT

(The story corrects paragraph three to say company reported Q2, not Q1, results)

By Manas Mishra

(Reuters) - Johnson & Johnson on Tuesday reported quarterly results that beat analysts' estimates on strong demand for cancer drug Darzalex and its COVID-19 vaccine, even as the company cut its full-year adjusted profit forecast due to a stronger dollar.

J&J joins other major U.S. multinationals with sizeable international operations, including Microsoft Corp and IBM, in warning that a stronger dollar would hurt overseas sales.

But J&J's shares rose 1% in morning trading as its strong... More